SEC Filing Analysis: REGENERON PHARMACEUTICALS, INC. (REGN)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director filed a notice of a proposed sale of 760 shares valued at $570,000, executed under a pre-arranged 10b5-1 trading plan.
• Market Impact: The transaction is immaterial relative to the company's market capitalization and is not expected to have any market impact.

Company Information

Field	Value
Company	REGENERON PHARMACEUTICALS, INC.
Ticker Symbol	REGN
CIK	0000872589
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Bassler Bonnie L
CIK	0001683607
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-20
Transaction Code	S (Proposed Sale)
Security Type	Common Stock
Shares Involved	760
Price Per Share	$750.00
Total Value	$570,000
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$570,000
% of Market Cap	0.00078%
Shares Transacted	760
% of Shares Outstanding	0.00073%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $72.89 billion, this $570,000 transaction is financially insignificant.
• Transaction Significance: The sale represents a negligible fraction of both the market cap and the total shares outstanding, falling far below the thresholds for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is extremely small and was conducted under a Rule 10b5-1 plan, which indicates it was pre-scheduled for personal financial management and not based on any new, non-public information.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
• Sentiment Indicator: Neutral. This is a routine, non-indicative insider transaction.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the sale is pursuant to a Rule 10b5-1 trading plan established on May 2, 2025. The shares to be sold were acquired via an option exercise on the same day as the proposed sale.